Canaccord Genuity cuts Alnylam Pharmaceuticals target price to $323 from $429
ALNY•Canaccord Genuity cut its target price for Alnylam Pharmaceuticals to $323 from $429.
Related News
Amentum expands defense and space operations in Colorado Springs
AMTM•
Agility Robotics expects Churchill Capital XI deal to close November 4
CCXI•
Fed's Barkin says US central bank's direction 'straightforward,' question is pace
TLT•
Goldman Sachs sees US existing home sales falling in 2027 as mortgage rates weigh
GS•
World Acceptance director Ken R. Bramlett Jr. reports sale of common shares worth $671,874.77
WRLD•